Thymoma related myasthenia gravis in humans and potential animal models

Experimental Neurology

Volumn 270, Issue , 2015, Pages 55-65

  Marx, Alexander ^a   Porubsky, Stefan ^a   Belharazem, Djeda ^a   Saruhan Direskeneli, Güher ^b   Schalke, Berthold ^c   Ströbel, Philipp ^d   Weis, Cleo Aron ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ISTANBUL UNIVERSITY   (Turkey)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

AIRE; Animal model; APS I; BUF Mna; Cat; Dog; Horse; Myasthenia gravis; Rat; Thymoma; Tiger

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; DOUBLE STRANDED RNA; HLA ANTIGEN CLASS 2; MYCOPHENOLATE MOFETIL; POTASSIUM CHANNEL; PROTEIN KINASE R; PYRIDOSTIGMINE; RNA HELICASE; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR FOXP3;

AIRE GENE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SELECTION; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOG DISEASE; EPITHELIUM CELL; FELINE MODEL; GENE; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION; MICROENVIRONMENT; MUTATION; MYASTHENIA GRAVIS; MYOID CELL; NONHUMAN; NUDE MOUSE; ONSET AGE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYMPTOMATOLOGY; T LYMPHOCYTE; THYMIC EPITHELIAL CELL; THYMOMA; THYMOMA ASSOCIATED MYASTHENIA GRAVIS; TREATMENT INDICATION; ANIMAL; CAT; COMPLICATION; DISEASE MODEL; DOG; IMMUNOLOGY; MOUSE;

ANIMALS; CATS; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MICE; MYASTHENIA GRAVIS; THYMOMA; THYMUS NEOPLASMS;

EID: 84939427681     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.02.010     Document Type: Review

References (140)

1. Aarli J.A., Stefansson K., Marton L.S., Wollmann R.L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin. Exp. Immunol. 1990, 82:284-288.
2. Abelson A.L., Shelton G.D., Whelan M.F., Cornejo L., Shaw S., O'Toole T.E. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. J. Vet. Emerg. Crit. Care 2009, 19:369-374.
3. Allan K., Masters N., Rivers S., Berry K., Routh A., Lamm C. T-lymphocyte-rich thymoma and myasthenia gravis in a Siberian tiger (Panthera tigris altaica). J. Comp. Pathol. 2014, 150:345-349.
4. Aronsohn M.G., Schunk K.L., Carpenter J.L., King N.W. Clinical and pathologic features of thymoma in 15 dogs. J. Am. Vet. Med. Assoc. 1984, 184:1355-1362.
5. Aschenbrenner K., D'Cruz L.M., Vollmann E.H., Hinterberger M., Emmerich J., Swee L.K., Rolink A., Klein L. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat. Immunol. 2007, 8:351-358.
6. Atwater S.W., Powers B.E., Park R.D., Straw R.C., Ogilvie G.K., Withrow S.J. Thymoma in dogs: 23 cases (1980-1991). J. Am. Vet. Med. Assoc. 1994, 205:1007-1013.
7. Avidan N., Le Panse R., Harbo H.F., Bernasconi P., Poulas K., Ginzburg E., Cavalcante P., Colleoni L., Baggi F., Antozzi C., et al. VAV1 and BAFF, via NFkappaB pathway, are genetic risk factors for myasthenia gravis. Ann. Clin. Transl. Neurol. 2014, 1:329-339.
8. Balandina A., Lecart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
9. Barnes R.D., Tuffrey M.A., Berry C.L. Auto-immune disease in (NZB×CFW) F1 mice. J. Pathol. Bacteriol. 1968, 95:391-403.
10. Batlivala T.P., Bacon N.J., Avery A.C., Barabas K., Gunn-Christie R.G., Conway J., Avery P.R. Paraneoplastic T cell lymphocytosis associated with a thymoma in a dog. J. Small Anim. Pract. 2010, 51:491-494.
11. Berrih-Aknin S., Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J. Autoimmun. 2014, 52:90-100.
12. Buckley C., Douek D., Newsom-Davis J., Vincent A., Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann. Neurol. 2001, 50:64-72.
13. Buckley C., Newsom-Davis J., Willcox N., Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 2001, 57:1579-1582.
14. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., Berrih-Aknin S., Bernasconi P., Aloisi F., Mantegazza R. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann. Neurol. 2010, 67:726-738.
15. Cheng M.H., Fan U., Grewal N., Barnes M., Mehta A., Taylor S., Husebye E.S., Murphy E.J., Anderson M.S. Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect. N. Engl. J. Med. 2010, 362:764-766.
16. Chuang W.Y., Strobel P., Gold R., Nix W., Schalke B., Kiefer R., Opitz A., Klinker E., Muller-Hermelink H.K., Marx A. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann. Neurol. 2005, 58:644-648.
17. Chuang W.Y., Strobel P., Belharazem D., Rieckmann P., Toyka K.V., Nix W., Schalke B., Gold R., Kiefer R., Klinker E., et al. The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun. 2009, 10:667-672.
18. Chuang W.Y., Strobel P., Bohlender-Willke A.L., Rieckmann P., Nix W., Schalke B., Gold R., Opitz A., Klinker E., Inoue M., et al. Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naive T cells. J. Autoimmun. 2014, 52:122-129.
19. Cufi P., Dragin N., Weiss J.M., Martinez-Martinez P., De Baets M.H., Roussin R., Fadel E., Berrih-Aknin S., Le Panse R. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann. Neurol. 2013, 73:281-293.
20. Cufi P., Soussan P., Truffault F., Fetouchi R., Robinet M., Fadel E., Berrih-Aknin S., Le Panse R. Thymoma-associated myasthenia gravis: on the search for a pathogen signature. J. Autoimmun. 2014, 52:29-35.
21. Dardenne M., Savino W., Bach J.F. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. Am. J. Pathol. 1987, 126:194-198.
22. Darke P.G., McCullagh K.G., Geldart P.H. Myasthenia gravis, thymoma and myositis in a dog. Vet. Rec. 1975, 97:392-393.
23. Day M.J. Review of thymic pathology in 30 cats and 36 dogs. J. Small Anim. Pract. 1997, 38:393-403.
24. den Bakker M.A., Roden A.C., Marx A., Marino M. Histologic classification of thymoma: a practical guide for routine cases. J. Thorac. Oncol. 2014, 9(9):S125-S130.
25. Ezaki T., Oki S., Matsuda Y., Desaki J. Age changes of neuromuscular junctions in the extensor digitorum longus muscle of spontaneous thymoma BUF/Mna rats. A scanning and transmission electron microscopic study. Virchows Arch. 2000, 437:388-395.
26. Farrugia M.E., Vincent A. Autoimmune mediated neuromuscular junction defects. Curr. Opin. Neurol. 2010, 23:489-495.
27. Fierabracci A. Recent insights into the role and molecular mechanisms of the autoimmune regulator (AIRE) gene in autoimmunity. Autoimmun. Rev. 2011, 10:137-143.
28. Florizoone K. Thymoma-associated exfoliative dermatitis in a rabbit. Vet. Dermatol. 2005, 16:281-284.
29. Forster-Van Hijfte M.A., Curtis C.F., White R.N. Resolution of exfoliative dermatitis and Malassezia pachydermatis overgrowth in a cat after surgical thymoma resection. J. Small Anim. Pract. 1997, 38:451-454.
30. Francis D., Barnes R.D., Kramer J.J. The thymoma-prone (NZB×CFW) F1 mouse. J. Pathol. 1971, 103:188-193.
31. Fukui Y., Ishimoto T., Utsuyama M., Gyotoku T., Koga T., Nakao K., Hirokawa K., Katsuki M., Sasazuki T. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 1997, 6:401-410.
32. Gallardo E., Martinez-Hernandez E., Titulaer M.J., Huijbers M.G., Martinez M.A., Ramos A., Querol L., Diaz-Manera J., Rojas-Garcia R., Hayworth C.R., et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun. Rev. 2014, 13:1003-1007.
33. Garlepp M.J., Kay P.H., Farrow B.R., Dawkins R.L. Autoimmunity in spontaneous myasthenia gravis in dogs. Clin. Immunol. Immunopathol. 1984, 31:301-306.
34. Gasperi C., Melms A., Schoser B., Zhang Y., Meltoranta J., Risson V., Schaeffer L., Schalke B., Kroger S. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014, 82:1976-1983.
35. Gianchecchi E., Palombi M., Fierabracci A. The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. Autoimmun. Rev. 2013, 12:717-725.
36. Giraud M., Taubert R., Vandiedonck C., Ke X., Levi-Strauss M., Pagani F., Baralle F.E., Eymard B., Tranchant C., Gajdos P., et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007, 448:934-937.
37. Gores B.R., Berg J., Carpenter J.L., Aronsohn M.G. Surgical treatment of thymoma in cats: 12 cases (1987-1992). J. Am. Vet. Med. Assoc. 1994, 204:1782-1785.
38. Graus F., Dalmau J. Paraneoplastic neurological syndromes. Curr. Opin. Neurol. 2012, 25(6):795-801.
39. Gregersen P.K., Kosoy R., Lee A.T., Lamb J., Sussman J., McKee D., Simpfendorfer K.R., Pirskanen-Matell R., Piehl F., Pan-Hammarstrom Q., et al. Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann. Neurol. 2012, 72(6):927-935.
40. Hadlow W.J. High prevalence of thymoma in the dairy goat. Report of seventeen cases. Vet. Pathol. 1978, 15:153-169.
41. Hall G.A., Howell J.M., Lewis D.G. Thymoma with myasthenia gravis in a dog. J. Pathol. 1972, 108:177-180.
42. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 2011, 69:418-422.
43. Hill P.B., Brain P., Collins D., Fearnside S., Olivry T. Putative paraneoplastic pemphigus and myasthenia gravis in a cat with a lymphocytic thymoma. Vet. Dermatol. 2013, 24:646-649.
44. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 2001, 7:365-368.
45. Hoffacker V., Schultz A., Tiesinga J.J., Gold R., Schalke B., Nix W., Kiefer R., Muller-Hermelink H.K., Marx A. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 2000, 96:3872-3879.
46. Hohlfeld R., Wekerle H. Reflections on the "intrathymic pathogenesis" of myasthenia gravis. J. Neuroimmunol. 2008, 201-202:21-27.
47. Hohlfeld R., Toyka K.V., Heininger K., Grosse-Wilde H., Kalies I. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 1984, 310:244-246.
48. Holbro A., Jauch A., Lardinois D., Tzankov A., Dirnhofer S., Hess C. High prevalence of infections and autoimmunity in patients with thymoma. Hum. Immunol. 2012, 73:287-290.
49. Inoue M., Matsuyama M., Shiono H., Honda O., Sumikawa H., Tomiyama N., Okumura M. Characterization of T cell maturity in thymic epithelial cell tumors from BUF/Mna spontaneous thymoma rats and BUF/Mna-Rnu/+ rats showing delayed thymomagenesis. Int. J. Clin. Exp. Pathol. 2010, 3:587-592.
50. Jones J.V. Plasmapheresis: great economy in the use of horses. N. Engl. J. Med. 1977, 297:1173-1175.
51. Khaki F., Javanbakht J., Sasani F., Gharagozlou M.J., Bahrami A., Moslemzadeh H., Sheikhzadeh R. Cervical type AB thymoma (Mixed) tumour diagnosis in a mynah as a model to study human: clinicohistological, immunohistochemical and cytohistopathological study. Diagn. Pathol. 2013, 8:98.
52. Kirchner T., Schalke B., Melms A., von Kugelgen T., Muller-Hermelink H.K. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1986, 52:237-257.
53. Kirchner T., Hoppe F., Muller-Hermelink H.K., Schalke B., Tzartos S. Acetylcholine receptor epitopes on epithelial cells of thymoma in myasthenia gravis. Lancet 1987, 1:218.
54. Kisand K., Boe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., Ersvaer E., Perheentupa J., Erichsen M.M., Bratanic N., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 2010, 207:299-308.
55. Kisand K., Lilic D., Casanova J.L., Peterson P., Meager A., Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur. J. Immunol. 2011, 41:1517-1527.
56. Klein R., Marx A., Strobel P., Schalke B., Nix W., Willcox N. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum. Immunol. 2013, 74:1184-1193.
57. Kotani Y., Sato J., Wako Y., Tsuchitani M. Mixed thymoma in a young cynomolgus monkey (Macaca fascicularis). J. Toxicol. Pathol. 2010, 23:141-145.
58. Kuo T.T., Chan J.K. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile. Am. J. Surg. Pathol. 1998, 22:1474-1481.
59. Kusner L.L., Ciesielski M.J., Marx A., Kaminski H.J., Fenstermaker R.A. Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. PLoS One 2014, 9:e102231.
60. Kyewski B., Peterson P. Aire, master of many trades. Cell 2010, 140:24-26.
61. Lainesse M.F., Taylor S.M., Myers S.L., Haines D., Fowler J.D. Focal myasthenia gravis as a paraneoplastic syndrome of canine thymoma: improvement following thymectomy. J. Am. Anim. Hosp. Assoc. 1996, 32:111-117.
62. Lee S.S., Park W.Y., Chi J.G., Seo J.W., Kim J.I., Kim C.W., Park S.H., Khang S.K., Cho K.J., Seo J.S., Jang J.J. Thymic epithelial tumor progression in an SV40T transgenic mouse model. Cortical thymoma-thymic carcinoma sequence. Virchows Arch. 1998, 432:33-42.
63. Leite M.I., Jones M., Strobel P., Marx A., Gold R., Niks E., Verschuuren J.J., Berrih-Aknin S., Scaravilli F., Canelhas A., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am. J. Pathol. 2007, 171:893-905.
64. Levinson A.I., Zheng Y., Gaulton G., Moore J., Pletcher C.H., Song D., Wheatley L.M. A new model linking intrathymic acetylcholine receptor expression and the pathogenesis of myasthenia gravis. Ann. N. Y. Acad. Sci. 2003, 998:257-265.
65. Liu Y., Zhang H., Zhang P., Meng F., Chen Y., Wang Y., Yao Y., Qi B. Autoimmune regulator expression in thymomas with or without autoimmune disease. Immunol. Lett. 2014, 161:50-56.
66. Maclennan C.A., Vincent A., Marx A., Willcox N., Gilhus N.E., Newsom-Davis J., Beeson D. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J. Neuroimmunol. 2008, 201-202:28-32.
67. Maggi L., Andreetta F., Antozzi C., Confalonieri P., Cornelio F., Scaioli V., Mantegazza R. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. Neuromuscul. Disord. 2008, 18:678-680.
68. Maniaol A.H., Elsais A., Lorentzen A.R., Owe J.F., Viken M.K., Saether H., Flam S.T., Brathen G., Kampman M.T., Midgard R., et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 2012, 7:e36603.
69. Marx A., Wilisch A., Schultz A., Greiner A., Magi B., Pallini V., Schalke B., Toyka K., Nix W., Kirchner T., Muller-Hermelink H.K. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am. J. Pathol. 1996, 148:1839-1850.
70. Marx A., Wilisch A., Schultz A., Gattenlohner S., Nenninger R., Muller-Hermelink H.K. Pathogenesis of myasthenia gravis. Virchows Arch. 1997, 430:355-364.
71. Marx A., Willcox N., Leite M.I., Chuang W.Y., Schalke B., Nix W., Strobel P. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010, 43:413-427.
72. Marx A., Strobel P., Badve S.S., Chalabreysse L., Chan J.K., Chen G., de Leval L., Detterbeck F., Girard N., Huang J., et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J. Thorac. Oncol. 2014, 9:596-611.
73. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., Ohtsuka T., Nishida M., Hirano T., Utsumi H. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J. Neuroimmunol. 2010, 225:123-131.
74. Matsuyama M., Yamada C., Kojima A. Possible single dosage effects of the nude gene: suppression of spontaneous development of thymoma and nephropathy in BUF/Mna-rnu/+ rats. Jpn. J. Cancer Res. 1987, 78:40-44.
75. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., Willcox N. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 2003, 132:128-136.
76. Meinl E., Klinkert W.E., Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am. J. Pathol. 1991, 139:995-1008.
77. Mellanby R.J., Mellor P.J., Herrtage M.E. What is your diagnosis? Thymoma. J. Small Anim. Pract. 2004, 45(12). 589, 626-628.
78. Melms A., Malcherek G., Gern U., Wietholter H., Muller C.A., Schoepfer R., Lindstrom J. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit. Ann. Neurol. 1992, 31:311-318.
79. Meyer M., Hols A.K., Liersch B., Leistner R., Gellert K., Schalke B., Marx A., Niedobitek G. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann. Neurol. 2011, 70:515-518.
80. Moffet A.C. Metastatic thymoma and acquired generalized myasthenia gravis in a beagle. Can. Vet. J. 2007, 48:91-93.
81. Müller-Hermelink H.K., Engel P., Kuo T.T., Ströbel P., Marx A., Harris N.L., Möller P., Menestrina F., Shimosato Y., Asamura H., et al. Tumours of the thymus. World Health Organization Classification of Tumours: Pathology and Genetics Tumours of the Lung, Pleura, Thymus and Heart 2004, W.D. Travis, E. Brambilla, H.K. Müller-Hermelink, C.C. Harris (Eds.).
82. Nagvekar N., Moody A.M., Moss P., Roxanis I., Curnow J., Beeson D., Pantic N., Newsom-Davis J., Vincent A., Willcox N. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J. Clin. Invest. 1998, 101:2268-2277.
83. Paciello O., Maiolino P., Navas L., Papparell S. Acquired canine myasthenia gravis associated with thymoma: histological features and immunohistochemical localization of HLA type II and IgG. Vet. Res. Commun. 2003, 27(Suppl. 1):715-718.
84. Parker G.A., Casey H.W. Thymomas in domestic animals. Vet. Pathol. 1976, 13:353-364.
85. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
86. Petrini I., Meltzer P.S., Kim I.K., Lucchi M., Park K.S., Fontanini G., Gao J., Zucali P.A., Calabrese F., Favaretto A., et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat. Genet. 2014, 46:844-849.
87. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., Melms A., Kroger S. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 2012, 259:427-435.
88. Rennspiess D., Pujari S., Keijzers M., Abdul-Hamid M.A., Hochstenbag M., Dingemans A., Kurz A.K., Speel E., Haugg A., Pastrana D.V., et al. Detection of Human Polyomavirus 7 in human thymic epithelial tumors. J. Thorac. Oncol. 2014, 10(2):360-366.
89. Rigamonti A., Lauria G., Piamarta F., Fiumani A., Agostoni E. Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies. J. Neurol. Sci. 2011, 302:112-113.
90. Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis. 2011, 2011:474512.
91. Romi F., Bo L., Skeie G.O., Myking A., Aarli J.A., Gilhus N.E. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J. Neuroimmunol. 2002, 128:82-89.
92. Romi F., Skeie G.O., Gilhus N.E., Aarli J.A. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch. Neurol. 2005, 62:442-446.
93. Roxanis I., Micklem K., Willcox N. True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: implications for immunopathogenesis. J. Neuroimmunol. 2001, 112:163-173.
94. Roxanis I., Micklem K., McConville J., Newsom-Davis J., Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J. Neuroimmunol. 2002, 125:185-197.
95. Sabbir M.G., Prieditis H., Ravinsky E., Mowat M.R. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer. PLoS One 2012, 7:e40302.
96. Saka E., Topcuoglu M.A., Akkaya B., Galati A., Onal M.Z., Vincent A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 65:782-783. (author reply 782-783).
97. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
98. Savino W., Manganella G., Verley J.M., Wolff A., Berrih S., Levasseur P., Binet J.P., Dardenne M., Bach J.F. Thymoma epithelial cells secrete thymic hormone but do not express class II antigens of the major histocompatibility complex. J. Clin. Invest. 1985, 76:1140-1146.
99. Scarpino S., Di Napoli A., Stoppacciaro A., Antonelli M., Pilozzi E., Chiarle R., Palestro G., Marino M., Facciolo F., Rendina E.A., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin. Exp. Immunol. 2007, 149:504-512.
100. Scheijen B., Bronk M., van der Meer T., De Jong D., Bernards R. High incidence of thymic epithelial tumors in E2F2 transgenic mice. J. Biol. Chem. 2004, 279:10476-10483.
101. Schluep M., Willcox N., Vincent A., Dhoot G.K., Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann. Neurol. 1987, 22:212-222.
102. Schwartz J.A., Solomon J.A., Henkelman K., Leininger J.R., Iverson W.O. Spontaneous thymoma in a juvenile cynomolgus macaque (Macaca fascicularis). Toxicol. Pathol. 2011, 39:706-710.
103. Scott-Moncrieff J.C., Cook J.R., Lantz G.C. Acquired myasthenia gravis in a cat with thymoma. J. Am. Vet. Med. Assoc. 1990, 196:1291-1293.
104. Shelton G.D., Skeie G.O., Kass P.H., Aarli J.A. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. Vet. Immunol. Immunopathol. 2001, 78:97-105.
105. Shiono H., Wong Y.L., Matthews I., Liu J.L., Zhang W., Sims G., Meager A., Beeson D., Vincent A., Willcox N. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 2003, 15:903-913.
106. Siara J., Rudel R., Marx A. Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. Neurology 1991, 41:128-131.
107. Singh A., Boston S.E., Poma R. Thymoma-associated exfoliative dermatitis with post-thymectomy myasthenia gravis in a cat. Can. Vet. J. 2010, 51:757-760.
108. Sommer N., Harcourt G.C., Willcox N., Beeson D., Newsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991, 41:1270-1276.
109. Spuler S., Sarropoulos A., Marx A., Hohlfeld R., Wekerle H. Thymoma-associated myasthenia gravis. Transplantation of thymoma and extrathymomal thymic tissue into SCID mice. Am. J. Pathol. 1996, 148:1359-1365.
110. Stenner V.J., Parry B.W., Holloway S.A. Acquired myasthenia gravis associated with a non-invasive thymic carcinoma in a dog. Aust. Vet. J. 2003, 81:543-546.
111. Strauss A.J., Snell K.C., Duntley B.J., Soban E.J., Stewart H.L. Spontaneous thymoma, polymyositis, and serum-autoantibodies to striated muscle in the rodent, subgenus Praomys (Mastomys) natalensis. Similarities to thymoma with myasthenia gravis in man. Lancet 1968, 1:1126-1129.
112. Strobel P., Helmreich M., Menioudakis G., Lewin S.R., Rudiger T., Bauer A., Hoffacker V., Gold R., Nix W., Schalke B., et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 2002, 100:159-166.
113. Strobel P., Bauer A., Puppe B., Kraushaar T., Krein A., Toyka K., Gold R., Semik M., Kiefer R., Nix W., et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J. Clin. Oncol. 2004, 22:1501-1509.
114. Strobel P., Rosenwald A., Beyersdorf N., Kerkau T., Elert O., Murumagi A., Sillanpaa N., Peterson P., Hummel V., Rieckmann P., et al. Selective loss of regulatory T cells in thymomas. Ann. Neurol. 2004, 56:901-904.
115. Strobel P., Murumagi A., Klein R., Luster M., Lahti M., Krohn K., Schalke B., Nix W., Gold R., Rieckmann P., et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J. Pathol. 2007, 211:563-571.
116. Strobel P., Chuang W.Y., Chuvpilo S., Zettl A., Katzenberger T., Kalbacher H., Rieckmann P., Nix W., Schalke B., Gold R., et al. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann. N. Y. Acad. Sci. 2008, 1132:143-156.
117. Strobel P., Hartmann E., Rosenwald A., Kalla J., Ott G., Friedel G., Schalke B., Kasahara M., Tomaru U., Marx A. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology 2014, 64:557-566.
118. Tackenberg B., Kruth J., Bartholomaeus J.E., Schlegel K., Oertel W.H., Willcox N., Hemmer B., Sommer N. Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis. Eur. J. Immunol. 2007, 37:849-863.
119. Tackenberg B., Schlegel K., Happel M., Eienbroker C., Gellert K., Oertel W.H., Meager A., Willcox N., Sommer N. Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients. J. Neuroimmunol. 2009, 216:85-91.
120. Taguchi O., Kontani K., Ikeda H., Matsuyama M. An intrinsic thymic epithelial abnormality is responsible for the spontaneous development of predominantly lymphocytic thymomas in BUF/Mna rats. Jpn. J. Cancer Res. 1992, 83:1166-1171.
121. Tanaka H., Suzuki S., Ninomiya F., Matsubara K., Hakoi K. Spontaneous thymoma in a 10-week-old Sprague-Dawley rat. J. Toxicol. Pathol. 2012, 25:37-40.
122. Taylor T.G., Carpenter J.L. Thymoma in two ferrets. Lab. Anim. Sci. 1995, 45:363-365.
123. Teitz T., Chang J.C., Kan Y.W., Yen T.S. Thymic epithelial neoplasms in transgenic mice expressing SV40 T antigen under the control of an erythroid-specific enhancer. J. Pathol. 1995, 177:309-315.
124. Vandiedonck C., Capdevielle C., Giraud M., Krumeich S., Jais J.P., Eymard B., Tranchant C., Gajdos P., Garchon H.J. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 2006, 59:404-407.
125. Vandiedonck C., Raffoux C., Eymard B., Tranchant C., Dulmet E., Krumeich S., Gajdos P., Garchon H.J. Association of HLA-A in autoimmune myasthenia gravis with thymoma. J. Neuroimmunol. 2009, 210:120-123.
126. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., Gomez A.M., De Baets M.H., Losen M. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun. Rev. 2013, 12:918-923.
127. Villaudy J., Schotte R., Legrand N., Spits H. Critical assessment of human antibody generation in humanized mouse models. J. Immunol. Methods 2014, 410:18-27.
128. Vincent A. Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems. J. Clin. Immunol. 2010, 30(Suppl. 1):S97-S102.
129. Vincent A., Solleveld H.A. Absence of anti-acetylcholine receptor antibodies in Praomys (Mastomys) natalensis. Clin. Exp. Immunol. 1981, 43:94-98.
130. Wernick M.B., Hilbe M., Kaufmann-Bart M., Albini S., Hoop R.K., Hatt J.M. Pathology in practice. Thymoma in a parrot. J. Am. Vet. Med. Assoc. 2013, 243:1117-1119.
131. Willcox N., Schluep M., Ritter M.A., Schuurman H.J., Newsom-Davis J., Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset?. Am. J. Pathol. 1987, 127:447-460.
132. Willcox N., Leite M.I., Kadota Y., Jones M., Meager A., Subrahmanyam P., Dasgupta B., Morgan B.P., Vincent A. Autoimmunizing mechanisms in thymoma and thymus. Ann. N. Y. Acad. Sci. 2008, 1132:163-173.
133. Williams C.L., Hay J.E., Huiatt T.W., Lennon V.A. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab. Invest. 1992, 66:331-336.
134. Wolff A.S., Karner J., Owe J.F., Oftedal B.E., Gilhus N.E., Erichsen M.M., Kampe O., Meager A., Peterson P., Kisand K., et al. Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. J. Immunol. 2014, 193:3880-3890.
135. Yamada T., Matsuyama M., Yanagida T., Kato K., Sugiura S., Kuroda M. Cervical thymuses exist, but no cervical thymomas develop in thoracic thymoma-prone BUF rats. Int. J. Exp. Pathol. 2011, 92:117-120.
136. Zettl A., Strobel P., Wagner K., Katzenberger T., Ott G., Rosenwald A., Peters K., Krein A., Semik M., Muller-Hermelink H.K., Marx A. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am. J. Pathol. 2000, 157:257-266.
137. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., Xiong W.C., Lisak R.P., Tzartos S.J., Mei L. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 2012, 69:445-451.
138. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun. Rev. 2013, 12:924-930.
139. Zisimopoulou P., Evangelakou P., Tzartos J., Lazaridis K., Zouvelou V., Mantegazza R., Antozzi C., Andreetta F., Evoli A., Deymeer F., et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 2014, 52:139-145.
140. Zitz J.C., Birchard S.J., Couto G.C., Samii V.F., Weisbrode S.E., Young G.S. Results of excision of thymoma in cats and dogs: 20 cases (1984-2005). J. Am. Vet. Med. Assoc. 2008, 232:1186-1192.